Patents Assigned to F-star Therapeutics Limited
  • FC BINDING FRAGMENTS COMPRISING A PD-L1 ANTIGEN-BINDING SITE
    Publication number: 20230406935
    Abstract: The application relates to specific binding members which bind to programmed death-ligand 1 (PD-L1). The specific binding members preferably comprise a PD-L1 antigen-binding site located in structural loops of a constant domain of the specific binding member. The specific binding members find application, for example, in the treatment of cancer, as well as infectious diseases, inflammation, diseases and conditions associated with inflammation, and inflammatory diseases.
    Type: Application
    Filed: December 8, 2022
    Publication date: December 21, 2023
    Applicant: F-star Therapeutics Limited
    Inventors: Mihriban Tuna, Francisca Wollerton Van Horck, Ryan Fiehler, Mustapha Faroudi, Frederick Akele, Fadi Badr, Cyril Privezentzev
  • Multivalent immunoglobulins
    Patent number: 11827720
    Abstract: The present invention provides a multivalent immunoglobulin or part thereof binding specifically to at least two cell surface molecules of a single cell with at least one modification in at least one structural loop region of the immunoglobulin determining binding to an epitope of the cell surface molecules wherein the unmodified immunoglobulin does not significantly bind to the epitope, its use and methods for producing it.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: November 28, 2023
    Assignee: F-star Therapeutics Limited
    Inventors: Florian Ruker, Gottfried Himmler, Gordana Wozniak-Knopp
  • EGFR BINDING MOLECULES
    Publication number: 20230357413
    Abstract: The application relates to specific binding members which bind the human epidermal growth factor receptor (EGFR). The specific binding members preferably comprise an EGFR antigen-binding site which may be located in two or more structural loops of a CH3 domain of the specific binding member. The specific binding members are expected to find application in the treatment of cancers expressing EGFR.
    Type: Application
    Filed: February 8, 2023
    Publication date: November 9, 2023
    Applicant: F-STAR THERAPEUTICS LIMITED
    Inventors: Mihriban Tuna, Kin-Mei Leung, Haijun Sun, Melanie Medcalf, Samine Isaac
  • EGFR binding molecules
    Patent number: 11629193
    Abstract: The application relates to specific binding members which bind the human epidermal growth factor receptor (EGFR). The specific binding members preferably comprise an EGFR antigen-binding site which may be located in two or more structural loops of a CH3 domain of the specific binding member. The specific binding members are expected to find application in the treatment of cancers expressing EGFR.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: April 18, 2023
    Assignee: F-star Therapeutics Limited
    Inventors: Mihriban Tuna, Kin-Mei Leung, Haijun Sun, Melanie Medcalf, Samine Isaac
  • FC binding fragments comprising a PD-L1 antigen-binding site
    Patent number: 11548948
    Abstract: The application relates to specific binding members which bind to programmed death-ligand (PD-L1). The specific binding members preferably comprise a PD-L1 antigen-binding site located in structural loops of a constant domain of the specific binding member. The specific binding members find application, for example, in the treatment of cancer, as well as infectious diseases, inflammation, diseases and conditions associated with inflammation, and inflammatory diseases.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: January 10, 2023
    Assignee: F-star Therapeutics Limited
    Inventors: Mihriban Tuna, Francisca Wollerton Van Horck, Ryan Fiehler, Mustapha Faroudi, Frederick Akele, Fadi Badr, Cyril Privezentzev
  • Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
    Patent number: 11499249
    Abstract: Libraries of immunoglobulins which each have one or more amino acid modifications in at least one structural loop region of such immunoglobulins, where the modified loop region specifically binds to an epitope of an antigen to which an unmodified immunoglobulin does not significantly bind.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: November 15, 2022
    Assignee: F-Star Therapeutics Limited
    Inventors: Gottfried Himmler, Florian Ruker, Gordana Wozniak-Knopp
  • DOSAGE REGIMES FOR THE ADMINISTRATION OF A LAG-3/PD-L1 BISPECIFIC ANTIBODY
    Publication number: 20220275092
    Abstract: The application relates to dosage regimes for the administration of an antibody molecule which binds programmed death-ligand 1 (PD-L1) and lymphocyte-activation gene 3 (LAG-3) and their medical use in the treatment of cancer in human patients.
    Type: Application
    Filed: May 14, 2020
    Publication date: September 1, 2022
    Applicant: F-star Therapeutics Limited
    Inventors: Michelle Morrow, Fiona Germaschewski, Daniel Gliddon, Kin-mei Leung, Cristian Gradinaru, Christopher Shepherd, Josefin-Beate Holz, Louis Kayitalire
  • BINDING MOLECULES BINDING PD-L1 AND LAG-3
    Publication number: 20220185894
    Abstract: The present invention relates to antibody molecules which bind to programmed death-ligand 1 (PD-L1) and lymphocyte-activation gene 3 (LAG-3). The antibody molecules preferably comprise a CDR-based antigen binding site for PD-L1, and a LAG-3 antigen binding site which may be located in two or more structural loops of a CH3 domain of the antibody molecule. The antibody molecules of the invention find application, for example, in cancer therapy.
    Type: Application
    Filed: November 23, 2021
    Publication date: June 16, 2022
    Applicant: F-star Therapeutics Limited
    Inventors: Jamie Campbell, Nikole Sandy, Mihriban Tuna, Francisca Wollerton Van Horck, Katy Louise Everett, Miguel Gaspar, Matthew Kraman, Katarzyna Kmiecik, Mustapha Faroudi, Natalie Fosh, Barbara Hebeis
  • LAG-3 BINDING MEMBERS
    Publication number: 20220185890
    Abstract: The present invention relates to specific binding members which bind to lymphocyte-activation gene 3 (LAG-3). The specific binding members preferably comprise a LAG-3 antigen-binding site which may be located in two or more structural loops of a CH3 domain of the specific binding member. The specific binding members of the invention find application, for example, in cancer therapy.
    Type: Application
    Filed: November 23, 2021
    Publication date: June 16, 2022
    Applicant: F-star Therapeutics Limited
    Inventors: Mihriban Tuna, Francisca Wollerton, Katy Everett, Miguel Gaspar, Matthew Kraman, Katarzyna Kmiecik, Natalie Fosh
  • Binding molecules binding PD-L1 and LAG-3
    Patent number: 11214620
    Abstract: The present invention relates to antibody molecules which bind to programmed death-ligand 1 (PD-L1) and lymphocyte-activation gene 3 (LAG-3). The antibody molecules preferably comprise a CDR-based antigen binding site for PD-L1, and a LAG-3 antigen binding site which may be located in two or more structural loops of a CH3 domain of the antibody molecule. The antibody molecules of the invention find application, for example, in cancer therapy.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: January 4, 2022
    Assignee: F-star Therapeutics Limited
    Inventors: Jamie Campbell, Nikole Sandy, Mihriban Tuna, Francisca Wollerton Van Horck, Katy Louise Everett, Miguel Gaspar, Matthew Kraman, Katarzyna Kmiecik, Mustapha Faroudi, Natalie Fosh, Barbara Hebeis
  • LAG-3 binding members
    Patent number: 11214618
    Abstract: The present invention relates to specific binding members which bind to lymphocyte-activation gene 3 (LAG-3). The specific binding members preferably comprise a LAG-3 antigen-binding site which may be located in two or more structural loops of a CH3 domain of the specific binding member. The specific binding members of the invention find application, for example, in cancer therapy.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: January 4, 2022
    Assignee: F-star Therapeutics Limited
    Inventors: Mihriban Tuna, Francisca Wollerton Van Horck, Katy Louise Everett, Miguel Gaspar, Matthew Kraman, Katarzyna Kmiecik, Natalie Fosh